Report on the risk assessment of N-(1‑phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl) in the framework of the Council Decision on new psychoactive substances


This publication presents the data and findings of the risk assessment on N-(1‑phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl), carried out by the extended Scientific Committee of the EMCDDA on 22 February 2017. On the basis of the Risk Assessment Report — and on the initiative of the European Commission — on 25 September 2017, the Council decided that acryloylfentanyl should be subject to control measures across the Member States.

Download as PDF

Table of contents

  • Foreword
  • EMCDDA actions on monitoring and responding to new drugs
  • EMCDDA–Europol Joint Report on acryloylfentanyl: a summary
  • Risk Assessment Report of a new psychoactive substance: acryloylfentanyl
  • Annex 1: Technical report on acryloylfentanyl
  • Council Decision on subjecting acryloylfentanyl to control measures
  • Participants of the risk assessment meeting